CA2973540C — Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Assigned to Novartis AG · Expires 2025-07-08 · 1y expired
What this patent protects
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker. In some embodiments, siponimod is for administration via an initial titration regimen, followed by a regimen wherein the beta-blocker is adde…
USPTO Abstract
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker. In some embodiments, siponimod is for administration via an initial titration regimen, followed by a regimen wherein the beta-blocker is added to the patient's therapy on, at the earliest, day 1of a maintenance regimen.
Drugs covered by this patent
- Mayzent (SIPONIMOD) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.